Please login to the form below

Not currently logged in
Email:
Password:

onartuzumab

This page shows the latest onartuzumab news and features for those working in and with pharma, biotech and healthcare.

Deaths cause Amgen to drop stomach cancer drug

Deaths cause Amgen to drop stomach cancer drug

Another drug acting via the HGF/SF:MET pathway - Roche/Genentech's onartuzumab - suffered a setback earlier this year although in this case the problem was a lack of efficacy in

Latest news

  • Roche drug fails in lung cancer trial Roche drug fails in lung cancer trial

    Damages prospects for onartuzumab. A phase III trial of Roche's cancer prospect onartuzumab has been abandoned after the drug failed to show efficacy. ... In a statement, Roche said it is evaluating the implications of the METLung study results across

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics